Move to cut Colorado drug prices worries patients with rare diseases
The Colorado board’s choice of drugs to review elucidates one of the thorniest questions it must wrangle with: Would lowering the price tag for rare-disease medications lead manufacturers to pull out of the state or limit their availability?